PDIA2 (protein disulfide isomerase family A member 2) functions as an endoplasmic reticulum-localized enzyme responsible for protein folding and disulfide bond formation 1. The protein contains three N-linked glycosylation sites that modulate its dimerization and protein-protein interactions, though glycosylation is not required for ER localization 1. PDIA2 demonstrates significant clinical relevance across multiple cancers, with elevated expression associated with poor prognosis in prostate cancer, including higher Gleason scores, advanced staging, and lymph node metastasis 2. Conversely, in glioma, low PDIA2 expression correlates with worse patient outcomes and increased immune cell infiltration 3. In renal cell carcinoma, PDIA2 promotes tumor progression through regulation of the JNK signaling pathway, affecting cell proliferation, migration, and invasion 4. Notably, PDIA2 exhibits dual oncogenic functions in prostate cancer by promoting both venous thrombotic events and castrate-resistant progression through activation of tissue factor on extracellular vesicles 5. The protein has also been identified as a potential diagnostic biomarker in gallbladder carcinoma 6 and Behçet's disease 7. These findings suggest PDIA2 serves as both a protein folding chaperone and a cancer-associated factor with therapeutic potential.